Edwards Lifesciences Corporation EW
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -36.46% | 317.43% | -68.67% | -12.64% | -6.93% |
| Total Depreciation and Amortization | 4.40% | -4.22% | 8.93% | 2.89% | 4.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 123.30% | 68.42% | 23.67% | -22.36% | 726.58% |
| Change in Net Operating Assets | 127.20% | -290.09% | 31.97% | 231.63% | -19.90% |
| Cash from Operations | 1,388.36% | -90.29% | -21.40% | 97.69% | 3.50% |
| Capital Expenditure | -3.08% | 33.37% | -69.39% | -16.63% | 11.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 103.99% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,873.61% | 105.02% | 61.27% | -201.55% | -186.91% |
| Cash from Investing | -108.19% | 53.20% | 53.65% | -148.58% | -301.76% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -21.92% | 113.31% | -6.92% | -39.34% | 14.63% |
| Repurchase of Common Stock | 89.79% | -1,185.22% | 92.46% | -9,694.55% | 98.22% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -147.06% | 154.84% | 98.69% | -23,710.00% | 42.86% |
| Cash from Financing | 99.93% | -3,857.89% | 98.46% | -1,504.36% | 120.43% |
| Foreign Exchange rate Adjustments | -53.66% | 134.29% | 450.00% | 96.62% | -67.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 193.94% | -301.06% | 141.11% | -521.53% | 56.89% |